GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » EV-to-EBIT

Gala Pharmaceutical (Gala Pharmaceutical) EV-to-EBIT : -0.03 (As of Apr. 25, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Gala Pharmaceutical's Enterprise Value is $0.11 Mil. Gala Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in May. 2019 was $-3.53 Mil. Therefore, Gala Pharmaceutical's EV-to-EBIT for today is -0.03.

The historical rank and industry rank for Gala Pharmaceutical's EV-to-EBIT or its related term are showing as below:

GLPH's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.05
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Gala Pharmaceutical's Enterprise Value for the quarter that ended in May. 2019 was $3.40 Mil. Gala Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in May. 2019 was $-3.53 Mil. Gala Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2019 was -103.79%.

Gala Pharmaceutical EV-to-EBIT Historical Data

The historical data trend for Gala Pharmaceutical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical EV-to-EBIT Chart

Gala Pharmaceutical Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18
EV-to-EBIT
Get a 7-Day Free Trial -82.60 -3.34 -7.20 -5.20 -1.78

Gala Pharmaceutical Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.63 -2.48 -1.78 -1.03 -0.93

Competitive Comparison of Gala Pharmaceutical's EV-to-EBIT

For the Biotechnology subindustry, Gala Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gala Pharmaceutical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gala Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gala Pharmaceutical's EV-to-EBIT falls into.


Gala Pharmaceutical EV-to-EBIT Calculation

Gala Pharmaceutical's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.106/-3.529
=-0.03

Gala Pharmaceutical's current Enterprise Value is $0.11 Mil.
Gala Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in May. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gala Pharmaceutical  (OTCPK:GLPH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Gala Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2019 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: May. 2019 ) =EBIT / Enterprise Value (Q: May. 2019 )
=-3.529/3.40019
=-103.79 %

Gala Pharmaceutical's Enterprise Value for the quarter that ended in May. 2019 was $3.40 Mil.
Gala Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in May. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gala Pharmaceutical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » EV-to-EBIT
Comparable Companies
LSE:PYC PRTX PPCB BTHE TSXV:IBT XCNQ:DOSE TSXV:APC RSPI XCNQ:LILY OBMP ASX:MEB XSAT:CLINE B AMBS WAR:RDG ASX:ACL TNTY TSXV:MFS VODG GOVX ASX:RAC
Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Website
https://www.galapharmaceuticals.com
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.